Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Judge Vetos Merck’s $200M Hep C Patent Win Over Gilead Due to ‘Fabricated’ Testimony

By Meg Snyder | June 8, 2016

A federal judge has reversed a jury’s verdict, which had Gilead Sciences paying $200 million to Merck & Co. for patent infringement over a drug compound that cures hepatitis C. According to sources, the judge concluded that Merck was involved in misconduct while trying to obtain patents for hepatitis C drugs. 

In March, the jury had originally awarded Merck $200 million after hearing R&D evidence of Pharmasset—a company Gilead bought in 2011. However, U.S. District Judge Beth Labson Freeman reopened the case last month when Gilead offered additional evidence of Merck’s misconduct. 

Judge Freeman’s new ruling was on account of new discoveries about a retired Merck scientist and lawyer. Fierce Pharma reports the following:

A retired Merck scientist and lawyer “intentionally fabricated testimony” about early discoveries that led to the development of next-generation hepatitis C drugs, including Gilead’s blockbuster duo, Harvoni and Sovaldi, the ruling states. And Merck supported the “bad faith conduct,” the judge said.

According to an article in the Wall Street Journal:

Judge Freeman largely sided with Gilead in her ruling on Monday, finding that Mr. Durette lied to Pharmasset by saying he wasn’t involved in Merck’s internal hepatitis C research, and that he subsequently lied about the 2004 conference call in a deposition and court testimony in the patent lawsuit.

“Since Merck made no contribution and assumed none of the risk in the discovery and development of sofosbuvir, we do not believe Merck is entitled to any amount of damages,” said Michele Rest, a Gilead spokeswoman. “We continue to believe the Merck patents are invalid.”

Merck says it plans to appeal. 

To read Judge Freeman’s 65-page order, filed in federal court in San Jose, Calif., on Monday, click here. 

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE